Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, April 17, 2015, 38 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.33 to $30,000,000,000.00.

Highlighted Stocks Traded by Insiders:

Agios Pharmaceuticals (AGIO) - FREE Research Report

Higgons John Duncan, who is Chief Operating Officer at Agios Pharmaceuticals, sold 6,583 shares at $99.54 on April 17, 2015. Following this transaction, the Chief Operating Officer owned 106,252 shares meaning that the stake was reduced by 5.83% with the 6,583-share transaction.

The shares most recently traded at $104.37, up $4.83, or 4.63% since the insider transaction. Historical insider transactions for Agios Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,806
  • 4-Week # shares sold: 4,852
  • 12-Week # shares bought: 1,806
  • 12-Week # shares sold: 11,852
  • 24-Week # shares bought: 1,806
  • 24-Week # shares sold: 60,852

The average volume for Agios Pharmaceuticals has been 612,100 shares per day over the past 30 days. Agios Pharmaceuticals has a market cap of $4.0 billion and is part of the health care sector and drugs industry. Shares are down 3.85% year-to-date as of the close of trading on Friday.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. Currently, there are 3 analysts who rate Agios Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGIO - FREE

TheStreet Quant Ratings rates Agios Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Agios Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NxStage Medical (NXTM) - FREE Research Report

Swan Winifred L, who is SVP and General Counsel at NxStage Medical, sold 500 shares at $18.41 on April 17, 2015. Following this transaction, the SVP and General Counsel owned 29,859 shares meaning that the stake was reduced by 1.65% with the 500-share transaction.

The shares most recently traded at $18.29, down $0.12, or 0.66% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 31,232

The average volume for NxStage Medical has been 401,200 shares per day over the past 30 days. NxStage Medical has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are up 1.51% year-to-date as of the close of trading on Friday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings rates NxStage Medical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full NxStage Medical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ebix (EBIX) - FREE Research Report

Rennes Fondation, who is 10% Owner at Ebix, bought 30,000 shares at $28.70 on April 17, 2015. Following this transaction, the 10% Owner owned 3.7 million shares meaning that the stake was boosted by 0.82% with the 30,000-share transaction.

The shares most recently traded at $28.63, down $0.07, or 0.25% since the insider transaction. Historical insider transactions for Ebix go as follows:

  • 4-Week # shares bought: 35,000
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 35,000
  • 12-Week # shares sold: 58,445
  • 24-Week # shares bought: 35,000
  • 24-Week # shares sold: 58,445

The average volume for Ebix has been 462,100 shares per day over the past 30 days. Ebix has a market cap of $1.0 billion and is part of the technology sector and computer software & services industry. Shares are up 68.45% year-to-date as of the close of trading on Friday.

Ebix, Inc. provides software and e-commerce solutions to the insurance industry. The stock currently has a dividend yield of 1.04%. The company has a P/E ratio of 17.2. Currently, there is 1 analyst who rates Ebix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EBIX - FREE

TheStreet Quant Ratings rates Ebix as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Ebix Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null